Paediatric drug formulations for poverty-related diseases – 2019

Funding under this call aims to support research on the adaptation of existing medicinal products (drugs), including off-patent products, to the specific needs of children (0-17 years of age) for any poverty-related disease within the scope of the EDCTP2 programme. Proposals were to include one (or more) clinical trials conducted in sub-Saharan Africa to assess the safety, efficacy and pharmacokinetics of the drug(s), and/or the development of age-appropriate formulations.

Call identifier: RIA2019PD

See the corresponding call text

ACOZI-KIDS
Towards a pediatric indication for children between 1 and 14 years of age for a safe, effective, all-oral single-dose treatment formulation of acoziborole for first and second stage gambiense human African trypanosomiasis (g-HAT)

Drugs for Neglected Diseases initiative, Geneva, Switzerland, with partners from the Democratic Republic of the Congo, France, Guinea, and Portugal 
Project coordinator: Dr Antoine Tarral
Starting date: 01 October 2020
Duration: 60 months
EDCTP grant amount: EUR 2,999,107
Grant agreement: RIA2019PD-2890

DPP
Developing paediatric primaquine

Chancellor, Masters and Scholars of the University of Oxford, Oxford, United Kingdom, with partners from Burkina Faso, Ethiopia, and France
Project coordinator: Dr W.R.J. Taylor
Starting date: 01 September 2020
Duration: 56 months
EDCTP grant amount: EUR 3,489,896
Grant agreement: RIA2019PD-2893
Project website

MiniMox
Treatment for all: Developing a paediatric formulation moxidectin for neglected infectious diseases

Luxembourg Institute of Health, Luxembourg, Luxembourg, with partners from Cameroon, Germany, Ghana, and the United Kingdom
Project coordinator: Dr Michel Vaillant
Starting date: 01 January 2021
Duration: 42 months
EDCTP grant amount: EUR 2,112,690
Grant agreement: RIA2019PD-2880